Blueprint Medicines Corporation
Symbool: 0HOJ.L
LSE
91.075
USDMarktprijs vandaag
-23.2788
Koers/Winst Verhouding
-0.1299
Koers/Winst Groei Verhouding
5.58B
MRK Kapitalisatie
- 0.00%
DIV Rendement
Blueprint Medicines Corporation (0HOJ-L) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 710.6 | 945 | 477.1 | |||||||||||
balance-sheet.row.short-term-investments | 0 | 639.4 | 825.3 | 267.2 | |||||||||||
balance-sheet.row.net-receivables | 0 | 43.2 | 36.9 | 37 | |||||||||||
balance-sheet.row.inventory | 0 | 21.2 | 29.7 | 21.8 | |||||||||||
balance-sheet.row.other-current-assets | 0 | 33.4 | 35 | 18.1 | |||||||||||
balance-sheet.row.total-current-assets | 0 | 808.4 | 1046.7 | 554 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 115.7 | 115.2 | 120.9 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 94.6 | 166.5 | 562.7 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 0 | 30.6 | 21.6 | 14.6 | |||||||||||
balance-sheet.row.total-non-current-assets | 0 | 240.9 | 303.3 | 698.2 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 0 | 1049.3 | 1349.9 | 1252.2 | |||||||||||
balance-sheet.row.account-payables | 0 | 4.7 | 2.7 | 8.3 | |||||||||||
balance-sheet.row.short-term-debt | 0 | 81.4 | 44.7 | 8.1 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 0 | 611 | 535.3 | 103.3 | |||||||||||
Deferred Revenue Non Current | 0 | 4.8 | 13.6 | 25.1 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 0 | 128 | 131.1 | 121.8 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 703.7 | 652 | 131.7 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 81.8 | 92.8 | 103.3 | |||||||||||
balance-sheet.row.total-liab | 0 | 918.6 | 835.2 | 281.5 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0 | 0.1 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.retained-earnings | 0 | -2339.9 | -1833 | -1275.4 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -3.5 | -10.4 | -4.1 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 2474 | 2358 | 2250.3 | |||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 130.6 | 514.7 | 970.7 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 1049.3 | 1349.9 | 1252.2 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 0 | 130.6 | 514.7 | 970.7 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||
Total Investments | 0 | 733.9 | 991.7 | 829.9 | |||||||||||
balance-sheet.row.total-debt | 0 | 774.1 | 672.8 | 111.4 | |||||||||||
balance-sheet.row.net-debt | 0 | 702.8 | 553.1 | -98.5 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -507 | -557.5 | -644.1 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 11.7 | 20.1 | 12.8 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | -126.1 | -87.8 | -67.3 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | 92.7 | 99 | 91.6 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | -41.1 | -53.8 | -23.7 | |||||||||||
cash-flows.row.account-receivables | 0 | -7.7 | -2.2 | -11.8 | |||||||||||
cash-flows.row.inventory | 0 | -4.4 | -8.9 | -12.6 | |||||||||||
cash-flows.row.account-payables | 0 | 1.9 | -5.8 | 4.2 | |||||||||||
cash-flows.row.other-working-capital | 0 | -31 | -36.8 | -3.5 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | 133.1 | 77.8 | 332 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -16.1 | -8.9 | -3.1 | |||||||||||
cash-flows.row.acquisitions-net | 0 | -290.1 | 0 | -258.2 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | -766.4 | -489.7 | -655.4 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 1056.5 | 349.4 | 690.8 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 290.1 | -0.3 | 0 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 274 | -149.5 | -225.9 | |||||||||||
cash-flows.row.debt-repayment | 0 | -97.9 | -553.6 | 0 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 21.3 | 8.2 | 50.7 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 424 | 50.7 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 119.2 | 561.8 | 50.7 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0.2 | -0.2 | -0.9 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | -48.4 | -90.2 | -474.7 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 71.3 | 119.7 | 209.9 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 119.7 | 209.9 | 684.6 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | -436.8 | -502.3 | -298.7 | |||||||||||
cash-flows.row.capital-expenditure | 0 | -16.1 | -8.9 | -3.1 | |||||||||||
cash-flows.row.free-cash-flow | 0 | -452.9 | -511.2 | -301.7 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 249.4 | 204 | 180.1 | |||||||||||
income-statement-row.row.cost-of-revenue | 0 | 24.5 | 46.9 | 38.5 | |||||||||||
income-statement-row.row.gross-profit | 0 | 224.9 | 157.2 | 141.6 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.operating-expenses | 0 | 711.2 | 694.7 | 783.5 | |||||||||||
income-statement-row.row.cost-and-expenses | 0 | 735.7 | 741.6 | 822.1 | |||||||||||
income-statement-row.row.interest-income | 0 | 32.8 | 17.7 | 2.4 | |||||||||||
income-statement-row.row.interest-expense | 0 | 51.6 | 16.8 | 0 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -19.7 | -14.8 | 0.9 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.total-operating-expenses | 0 | -19.7 | -14.8 | 0.9 | |||||||||||
income-statement-row.row.interest-expense | 0 | 51.6 | 16.8 | 0 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 11.7 | 20.1 | 12.8 | |||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 0 | -486.3 | -537.5 | -642 | |||||||||||
income-statement-row.row.income-before-tax | 0 | -506 | -552.3 | -641.1 | |||||||||||
income-statement-row.row.income-tax-expense | 0 | 1 | 5.2 | 3 | |||||||||||
income-statement-row.row.net-income | 0 | -507 | -557.5 | -644.1 |
Vaak gestelde vragen
Wat is Blueprint Medicines Corporation (0HOJ.L) totale activa?
Blueprint Medicines Corporation (0HOJ.L) totale activa is 1049250000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.898.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -1.022.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -1.562.
Wat is Blueprint Medicines Corporation (0HOJ.L) nettowinst (netto-inkomen)?
De nettowinst is -506984000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 774122000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 711196000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 0.000.